Clinical correlation of molecular (VEGF, FGF, PDGF, c-Myc, c-Kit, Ras, p53) expression in juvenile nasopharyngeal angiofibroma
- 124 Downloads
A molecular surrogate may exist for the clinical behaviour of juvenile nasopharyngeal angiofibroma (JNA).
In 9–14 cases, a ‘correlation’ of clinical behaviour with molecular expression (m-RNA expression through RT-PCR) of VEGF, FGF, PDGF, Ras, c-Myc, c-Kit and p53 was undertaken.
A comparison of the two extremes of expressions characterized some specific clinical phenotypes for every marker except c-Myc. A higher FGF was associated with post-adolescent presentation, smaller tumour size, enhanced haemorrhage and recurrence. A higher c-Kit was associated with adolescents, rapid growth, skull base involvement and recurrence. Enhanced Ras was associated with post-adolescence, smaller tumour size, skull base involvement and recurrence. Enhanced p53 and PDGF were associated with adolescents, early presentation and rapid progression. Higher VEGF expression was associated with skull base involvement and enhanced haemorrhage.
This study is currently the only evidence revealing a clinical molecular association in JNA and larger multicentric studies need to be performed to show a statistical significance.
KeywordsNasopharynx Angiofibroma VEGF FGF PDGF Ras C-Myc C-Kit P53
The principal author would like to acknowledge Praveen Pandey from CDRI for his efforts in generating the necessary laboratory data and while the basic molecular expression values have been published in the laryngoscope, the current study exclusively correlates the clinical parameters.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
- 15.Schreiber AB, Kenney J, Kowalski J, Thomas KA, Gimenez-Gallego G, Rios-Candelore M et al (1985) A unique family of endothelial cell polypeptide mitogens: the antigenic and receptor cross-reactivity of bovine endothelial cell growth factor, brain-derived acidic fibroblast growth factor, and eye-derived growth factor-II. J Cell Biol 101:1623–1626CrossRefGoogle Scholar
- 16.Kumar V (2010) Robbins and coltran pathologic basis of disease. Elsevier, Beijing, pp 88–89 (ISBN: 978-1-4160-3121-5)Google Scholar
- 29.Mishra A, Jaiswal R, Pandey A, Mishra SC (2018) Molecular interactions in juvenile nasopharyngeal angiofibroma: preliminary signature and relevant review. Eur Arch Otolaryngol (submitted)Google Scholar
- 31.Mishra A, Mishra SC, Verma V, Singh HP, Kumar S, Tripathi AM et al (2016) In defence of transpalatal, transpalatal-circumaxillary (transpterygopalatine) and transpalatal-circumaxillary-sublabial approaches to lateral extensions of juvenile nasopharyngeal angiofibroma. J Laryngol Otol 130:462–473CrossRefGoogle Scholar
- 35.Mishra A, Verma V (2018) Implication of embolization in residual disease in lateral extension of juvenile nasopharyngeal angiofibroma. J Oral Biol Craniofacial Res (submitted)Google Scholar
- 40.Mishra A, Singh V, Verma V, Pandey S, Trivedi R, Singh HP et al (2016) Current status and Clinical correlation of beta-catenin in juvenile nasopharyngeal angiofibroma. J Laryngol Otol 30:1–7Google Scholar
- 58.Mishra A, Sachadeva M, Jain A, Shukla NM, Pandey A (2016) Human papilloma virus in juvenile nasopharyngeal angiofibroma: possible recent trend. Am J Otolaryngol Head Neck Med Surg 37:317–322Google Scholar